Key clinical point: Age at onset of psoriatic arthritis (PsA) influences disease characteristics, with individuals developing PsA at older age having worse functionality and greater structural damage but a lower frequency of enthesitis and dactylitis.

Major finding: Patients with late vs early onset PsA showed greater structural damage (odds ratio [OR] 3.3; 95% CI 1.3-8.1), higher frequency of arthritis in upper limbs (OR 2.8; 95% CI 1.0-7.7), greater loss of functionality (OR 1.3; 95% CI 1.0-1.6), and lower frequency of enthesitis (OR 0.1; 95% CI 0-0.5) and sacroiliitis (OR 0.06; 95% CI 0-0.5).

Study details: This observational cross-sectional study included 231 patients with PsA with <10 years of disease duration from the REGISPONSER and RESPONDIA registries who were categorized into the early onset (≤40 years) or late onset (≥60 years) group depending on age at PsA symptom onset.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Puche-Larrubia MÁ et al. Differences between early vs  late-onset of psoriatic arthritis: Data from the respondia and regisponser registries. Joint Bone Spine. 2023;105563 (Mar 17). Doi: 10.1016/j.jbspin.2023.105563

Key clinical point: Age at onset of psoriatic arthritis (PsA) influences disease characteristics, with individuals developing PsA at older age having worse functionality and greater structural damage but a lower frequency of enthesitis and dactylitis.

Major finding: Patients with late vs early onset PsA showed greater structural damage (odds ratio [OR] 3.3; 95% CI 1.3-8.1), higher frequency of arthritis in upper limbs (OR 2.8; 95% CI 1.0-7.7), greater loss of functionality (OR 1.3; 95% CI 1.0-1.6), and lower frequency of enthesitis (OR 0.1; 95% CI 0-0.5) and sacroiliitis (OR 0.06; 95% CI 0-0.5).

Study details: This observational cross-sectional study included 231 patients with PsA with <10 years of disease duration from the REGISPONSER and RESPONDIA registries who were categorized into the early onset (≤40 years) or late onset (≥60 years) group depending on age at PsA symptom onset.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Puche-Larrubia MÁ et al. Differences between early vs  late-onset of psoriatic arthritis: Data from the respondia and regisponser registries. Joint Bone Spine. 2023;105563 (Mar 17). Doi: 10.1016/j.jbspin.2023.105563

Key clinical point: Age at onset of psoriatic arthritis (PsA) influences disease characteristics, with individuals developing PsA at older age having worse functionality and greater structural damage but a lower frequency of enthesitis and dactylitis.

Major finding: Patients with late vs early onset PsA showed greater structural damage (odds ratio [OR] 3.3; 95% CI 1.3-8.1), higher frequency of arthritis in upper limbs (OR 2.8; 95% CI 1.0-7.7), greater loss of functionality (OR 1.3; 95% CI 1.0-1.6), and lower frequency of enthesitis (OR 0.1; 95% CI 0-0.5) and sacroiliitis (OR 0.06; 95% CI 0-0.5).

Study details: This observational cross-sectional study included 231 patients with PsA with <10 years of disease duration from the REGISPONSER and RESPONDIA registries who were categorized into the early onset (≤40 years) or late onset (≥60 years) group depending on age at PsA symptom onset.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Puche-Larrubia MÁ et al. Differences between early vs  late-onset of psoriatic arthritis: Data from the respondia and regisponser registries. Joint Bone Spine. 2023;105563 (Mar 17). Doi: 10.1016/j.jbspin.2023.105563

Key clinical point: Vitamin D deficiency in patients with psoriatic arthritis (PsA) had worse impact on the retention rate of the first biological disease-modifying antirheumatic drug (bDMARD) and response to methotrexate and was associated with severe disease course in terms of sacroiliitis.

Major finding: The risk for discontinuation of the first bDMARD (hazard ratio [HR] 2.129; P  =  .011) and methotrexate discontinuation because of therapy failure (HR 2.168; P  =  .002) were significantly higher among patients with 25(OH)D level of ≤20 vs  20-30 and ≥30 ng/mL, with the prevalence of sacroiliitis being significantly higher in patients with 25(OH)D level of ≤20 vs  ≥30 ng/mL (P  =  .0001).

Study details: Findings are from a retrospective study including 233 patients with PsA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Rotondo C et al. Vitamin D status and psoriatic arthritis: Association with the risk for sacroiliitis and influence on the retention rate of methotrexate monotherapy and first biological drug survival—A retrospective study. Int J Mol Sci. 2023;24(6):5368 (Mar 10). Doi: 10.3390/ijms24065368

Key clinical point: Vitamin D deficiency in patients with psoriatic arthritis (PsA) had worse impact on the retention rate of the first biological disease-modifying antirheumatic drug (bDMARD) and response to methotrexate and was associated with severe disease course in terms of sacroiliitis.

Major finding: The risk for discontinuation of the first bDMARD (hazard ratio [HR] 2.129; P  =  .011) and methotrexate discontinuation because of therapy failure (HR 2.168; P  =  .002) were significantly higher among patients with 25(OH)D level of ≤20 vs  20-30 and ≥30 ng/mL, with the prevalence of sacroiliitis being significantly higher in patients with 25(OH)D level of ≤20 vs  ≥30 ng/mL (P  =  .0001).

Study details: Findings are from a retrospective study including 233 patients with PsA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Rotondo C et al. Vitamin D status and psoriatic arthritis: Association with the risk for sacroiliitis and influence on the retention rate of methotrexate monotherapy and first biological drug survival—A retrospective study. Int J Mol Sci. 2023;24(6):5368 (Mar 10). Doi: 10.3390/ijms24065368

Key clinical point: Vitamin D deficiency in patients with psoriatic arthritis (PsA) had worse impact on the retention rate of the first biological disease-modifying antirheumatic drug (bDMARD) and response to methotrexate and was associated with severe disease course in terms of sacroiliitis.

Major finding: The risk for discontinuation of the first bDMARD (hazard ratio [HR] 2.129; P  =  .011) and methotrexate discontinuation because of therapy failure (HR 2.168; P  =  .002) were significantly higher among patients with 25(OH)D level of ≤20 vs  20-30 and ≥30 ng/mL, with the prevalence of sacroiliitis being significantly higher in patients with 25(OH)D level of ≤20 vs  ≥30 ng/mL (P  =  .0001).

Study details: Findings are from a retrospective study including 233 patients with PsA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Rotondo C et al. Vitamin D status and psoriatic arthritis: Association with the risk for sacroiliitis and influence on the retention rate of methotrexate monotherapy and first biological drug survival—A retrospective study. Int J Mol Sci. 2023;24(6):5368 (Mar 10). Doi: 10.3390/ijms24065368

Key clinical point: Psoriatic arthritis with axial involvement (axPsA), defined either clinically or by imaging, showed distinct disease manifestations compared with axial spondyloarthritis (axSpA) plus psoriasis, indicating that axPsA and axSpA were distinct entities.

Major finding: Regardless of clinical or imaging definition used, patients with axPsA vs  axSpA+psoriasis were significantly more often women and older individuals and less often human leucocyte antigen-B27 positive (all P < .05), as well as had more frequent peripheral manifestations (P < .001) but less frequent uveitis (P < .001).

Study details: Findings are from the RABBIT-SpA, a prospective longitudinal observational study, including 1395 patients with PsA (359 patients had axial involvement) and 1428 patients with axSpA (181 patients had psoriasis).

Disclosures: The study was supported by AbbVie, Amgen, Biogen, Celltrion, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB, and Viatris. The authors did not report conflicts of interest.

Source: Regierer AC et al. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: An analysis of the German register RABBIT-SpA. RMD Open. 2023;9(1):e002837 (Mar 10). Doi: 10.1136/rmdopen-2022-002837.

Key clinical point: Psoriatic arthritis with axial involvement (axPsA), defined either clinically or by imaging, showed distinct disease manifestations compared with axial spondyloarthritis (axSpA) plus psoriasis, indicating that axPsA and axSpA were distinct entities.

Major finding: Regardless of clinical or imaging definition used, patients with axPsA vs  axSpA+psoriasis were significantly more often women and older individuals and less often human leucocyte antigen-B27 positive (all P < .05), as well as had more frequent peripheral manifestations (P < .001) but less frequent uveitis (P < .001).

Study details: Findings are from the RABBIT-SpA, a prospective longitudinal observational study, including 1395 patients with PsA (359 patients had axial involvement) and 1428 patients with axSpA (181 patients had psoriasis).

Disclosures: The study was supported by AbbVie, Amgen, Biogen, Celltrion, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB, and Viatris. The authors did not report conflicts of interest.

Source: Regierer AC et al. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: An analysis of the German register RABBIT-SpA. RMD Open. 2023;9(1):e002837 (Mar 10). Doi: 10.1136/rmdopen-2022-002837.

Key clinical point: Psoriatic arthritis with axial involvement (axPsA), defined either clinically or by imaging, showed distinct disease manifestations compared with axial spondyloarthritis (axSpA) plus psoriasis, indicating that axPsA and axSpA were distinct entities.

Major finding: Regardless of clinical or imaging definition used, patients with axPsA vs  axSpA+psoriasis were significantly more often women and older individuals and less often human leucocyte antigen-B27 positive (all P < .05), as well as had more frequent peripheral manifestations (P < .001) but less frequent uveitis (P < .001).

Study details: Findings are from the RABBIT-SpA, a prospective longitudinal observational study, including 1395 patients with PsA (359 patients had axial involvement) and 1428 patients with axSpA (181 patients had psoriasis).

Disclosures: The study was supported by AbbVie, Amgen, Biogen, Celltrion, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB, and Viatris. The authors did not report conflicts of interest.

Source: Regierer AC et al. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: An analysis of the German register RABBIT-SpA. RMD Open. 2023;9(1):e002837 (Mar 10). Doi: 10.1136/rmdopen-2022-002837.

Key clinical point: Triglyceride-glucose (TyG) index demonstrated a positive and robust association with the occurrence of carotid atherosclerosis (CA) and carotid artery plaque (CAP) in patients with psoriatic arthritis, independent of traditional cardiovascular and PsA risk factors.

Major finding: The TyG index was substantially higher in patients with vs  without CA (8.82 vs  8.54; P  =  .002) or CAP (8.88 vs  8.55; P  =  .001), with significant associations observed between continuous TyG and occurrence of CA (adjusted odds ratio [aOR] 2.69; 95% CI 1.02-7.11) and CAP (aOR 3.61; 95% CI 1.15-11.38).

Study details: Findings are from a cross-sectional study including 165 patients with confirmed diagnosis of PsA who underwent carotid ultrasound and had data available for corresponding TyG index.

Disclosures: This study was supported by the National Natural Science Foundation. The authors declared no conflicts of interest.

Source: Xie W et al. Association between triglyceride‑glucose index and carotid atherosclerosis in patients with psoriatic arthritis. Rheumatology (Oxford). 2023 (Mar 10). Doi: 10.1093/rheumatology/kead100

Key clinical point: Triglyceride-glucose (TyG) index demonstrated a positive and robust association with the occurrence of carotid atherosclerosis (CA) and carotid artery plaque (CAP) in patients with psoriatic arthritis, independent of traditional cardiovascular and PsA risk factors.

Major finding: The TyG index was substantially higher in patients with vs  without CA (8.82 vs  8.54; P  =  .002) or CAP (8.88 vs  8.55; P  =  .001), with significant associations observed between continuous TyG and occurrence of CA (adjusted odds ratio [aOR] 2.69; 95% CI 1.02-7.11) and CAP (aOR 3.61; 95% CI 1.15-11.38).

Study details: Findings are from a cross-sectional study including 165 patients with confirmed diagnosis of PsA who underwent carotid ultrasound and had data available for corresponding TyG index.

Disclosures: This study was supported by the National Natural Science Foundation. The authors declared no conflicts of interest.

Source: Xie W et al. Association between triglyceride‑glucose index and carotid atherosclerosis in patients with psoriatic arthritis. Rheumatology (Oxford). 2023 (Mar 10). Doi: 10.1093/rheumatology/kead100

Key clinical point: Triglyceride-glucose (TyG) index demonstrated a positive and robust association with the occurrence of carotid atherosclerosis (CA) and carotid artery plaque (CAP) in patients with psoriatic arthritis, independent of traditional cardiovascular and PsA risk factors.

Major finding: The TyG index was substantially higher in patients with vs  without CA (8.82 vs  8.54; P  =  .002) or CAP (8.88 vs  8.55; P  =  .001), with significant associations observed between continuous TyG and occurrence of CA (adjusted odds ratio [aOR] 2.69; 95% CI 1.02-7.11) and CAP (aOR 3.61; 95% CI 1.15-11.38).

Study details: Findings are from a cross-sectional study including 165 patients with confirmed diagnosis of PsA who underwent carotid ultrasound and had data available for corresponding TyG index.

Disclosures: This study was supported by the National Natural Science Foundation. The authors declared no conflicts of interest.

Source: Xie W et al. Association between triglyceride‑glucose index and carotid atherosclerosis in patients with psoriatic arthritis. Rheumatology (Oxford). 2023 (Mar 10). Doi: 10.1093/rheumatology/kead100

Key clinical point: Real-life study confirms the efficacy, safety, and high retention rate of secukinumab in patients with moderate-to-severe psoriatic arthritis (PsA), with male sex being an independent predictor of treatment response.

Major finding: The mean 28-Joint Disease Activity Score using C-reactive protein was significantly lower at week 52 vs  baseline (2.2 vs  5.8; P  =  .0001), suggesting remission, with men vs  women being more likely to achieve inactive disease or remission (odds ratio 5.16; 95% CI 1.35-26.63). The treatment retention rate at 1-year follow-up was 75%, with none of the patients discontinuing due to adverse events.

Study details: The data come from a retrospective study including 85 patients with moderate-to-severe PsA (n = 56) or ankylosing spondylitis (n = 29) treated with secukinumab and followed for 52 weeks.

Disclosures: This study did not receive any funding, except open access funding through Projekt DEAL, Germany. The authors declared no conflicts of interest.

Source: Molica Colella F et al. Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: A 52-week real-life study in an Italian cohort. Adv Rheumatol. 2023;63(1):15 (Mar 27). Doi: 10.1186/s42358-023-00295-2

Key clinical point: Real-life study confirms the efficacy, safety, and high retention rate of secukinumab in patients with moderate-to-severe psoriatic arthritis (PsA), with male sex being an independent predictor of treatment response.

Major finding: The mean 28-Joint Disease Activity Score using C-reactive protein was significantly lower at week 52 vs  baseline (2.2 vs  5.8; P  =  .0001), suggesting remission, with men vs  women being more likely to achieve inactive disease or remission (odds ratio 5.16; 95% CI 1.35-26.63). The treatment retention rate at 1-year follow-up was 75%, with none of the patients discontinuing due to adverse events.

Study details: The data come from a retrospective study including 85 patients with moderate-to-severe PsA (n = 56) or ankylosing spondylitis (n = 29) treated with secukinumab and followed for 52 weeks.

Disclosures: This study did not receive any funding, except open access funding through Projekt DEAL, Germany. The authors declared no conflicts of interest.

Source: Molica Colella F et al. Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: A 52-week real-life study in an Italian cohort. Adv Rheumatol. 2023;63(1):15 (Mar 27). Doi: 10.1186/s42358-023-00295-2

Key clinical point: Real-life study confirms the efficacy, safety, and high retention rate of secukinumab in patients with moderate-to-severe psoriatic arthritis (PsA), with male sex being an independent predictor of treatment response.

Major finding: The mean 28-Joint Disease Activity Score using C-reactive protein was significantly lower at week 52 vs  baseline (2.2 vs  5.8; P  =  .0001), suggesting remission, with men vs  women being more likely to achieve inactive disease or remission (odds ratio 5.16; 95% CI 1.35-26.63). The treatment retention rate at 1-year follow-up was 75%, with none of the patients discontinuing due to adverse events.

Study details: The data come from a retrospective study including 85 patients with moderate-to-severe PsA (n = 56) or ankylosing spondylitis (n = 29) treated with secukinumab and followed for 52 weeks.

Disclosures: This study did not receive any funding, except open access funding through Projekt DEAL, Germany. The authors declared no conflicts of interest.

Source: Molica Colella F et al. Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: A 52-week real-life study in an Italian cohort. Adv Rheumatol. 2023;63(1):15 (Mar 27). Doi: 10.1186/s42358-023-00295-2

Key clinical point: Tofacitinib was more effective and as safe as placebo in men and women with psoriatic arthritis (PsA); however, men were more likely to achieve minimal disease activity (MDA) with tofacitinib due to differences in baseline disease activity.

Major finding: At 3 months, tofacitinib was more efficacious than placebo irrespective of sex (P < .001); however, MDA was achieved by a higher proportion of men vs  women receiving tofacitinib (P < .05), although the American College of Rheumatology 20/50/70 response was comparable. The incidence of treatment-emergent adverse events was similar in men and women receiving tofacitinib at doses of 5 mg (67.5% and 70.2%, respectively) or 10 mg (70.0% and 72.8%, respectively) twice daily.

Study details: This post hoc analysis of data pooled from phase 3 randomized controlled trials included 816 patients with PsA who received tofacitinib, adalimumab, or placebo.

Disclosures: This study was sponsored by Pfizer. Some authors declared being employees, holding shares, or having other ties with various sources, including Pfizer.

Source: Eder L et al. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: A post-hoc analysis of phase 3 trials and long-term extension. RMD Open. 2023;9:e002718 (Mar 23). Doi: 10.1136/rmdopen-2022-002718

Key clinical point: Tofacitinib was more effective and as safe as placebo in men and women with psoriatic arthritis (PsA); however, men were more likely to achieve minimal disease activity (MDA) with tofacitinib due to differences in baseline disease activity.

Major finding: At 3 months, tofacitinib was more efficacious than placebo irrespective of sex (P < .001); however, MDA was achieved by a higher proportion of men vs  women receiving tofacitinib (P < .05), although the American College of Rheumatology 20/50/70 response was comparable. The incidence of treatment-emergent adverse events was similar in men and women receiving tofacitinib at doses of 5 mg (67.5% and 70.2%, respectively) or 10 mg (70.0% and 72.8%, respectively) twice daily.

Study details: This post hoc analysis of data pooled from phase 3 randomized controlled trials included 816 patients with PsA who received tofacitinib, adalimumab, or placebo.

Disclosures: This study was sponsored by Pfizer. Some authors declared being employees, holding shares, or having other ties with various sources, including Pfizer.

Source: Eder L et al. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: A post-hoc analysis of phase 3 trials and long-term extension. RMD Open. 2023;9:e002718 (Mar 23). Doi: 10.1136/rmdopen-2022-002718

Key clinical point: Tofacitinib was more effective and as safe as placebo in men and women with psoriatic arthritis (PsA); however, men were more likely to achieve minimal disease activity (MDA) with tofacitinib due to differences in baseline disease activity.

Major finding: At 3 months, tofacitinib was more efficacious than placebo irrespective of sex (P < .001); however, MDA was achieved by a higher proportion of men vs  women receiving tofacitinib (P < .05), although the American College of Rheumatology 20/50/70 response was comparable. The incidence of treatment-emergent adverse events was similar in men and women receiving tofacitinib at doses of 5 mg (67.5% and 70.2%, respectively) or 10 mg (70.0% and 72.8%, respectively) twice daily.

Study details: This post hoc analysis of data pooled from phase 3 randomized controlled trials included 816 patients with PsA who received tofacitinib, adalimumab, or placebo.

Disclosures: This study was sponsored by Pfizer. Some authors declared being employees, holding shares, or having other ties with various sources, including Pfizer.

Source: Eder L et al. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: A post-hoc analysis of phase 3 trials and long-term extension. RMD Open. 2023;9:e002718 (Mar 23). Doi: 10.1136/rmdopen-2022-002718

Key clinical point: COVID-19 vaccination was not associated with the worsening of disease activity in patients with psoriatic arthritis (PsA) who were treated with targeted therapies; however, COVID-19 vaccination may worsen disease activity in patients treated with interleukin-12/23 inhibitors (IL-12/23-i).

Major finding: The flare rate was not significantly different in the 6 months post-vaccination vs  the pre-vaccination period (P  =  .797), with no significant change in disease activity score in 28 joints before or after vaccination in the overall population. However, COVID-19 vaccination significantly worsened disease activity in patients treated with IL-12/23-i vs  tumor necrosis factor inhibitor (P  =  .019).

Study details: The data come from a prospective observational study including 1765 patients total with PsA (n = 587) or rheumatoid arthritis (n = 1178) treated with targeted therapies who were vaccinated for COVID-19 with any of the available vaccines.

Disclosures: This study was funded by Bristol-Myers Squibb, Galapagos Biopharma Spain SLU, and Roche Farma. Two authors reported ties with various sources, including Galapagos or Roche.

Source: Álvaro-Gracia JM et al. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study. RMD Open. 2023;9(1):e002936 (Mar 16). Doi: 10.1136/rmdopen-2022-002936

Key clinical point: COVID-19 vaccination was not associated with the worsening of disease activity in patients with psoriatic arthritis (PsA) who were treated with targeted therapies; however, COVID-19 vaccination may worsen disease activity in patients treated with interleukin-12/23 inhibitors (IL-12/23-i).

Major finding: The flare rate was not significantly different in the 6 months post-vaccination vs  the pre-vaccination period (P  =  .797), with no significant change in disease activity score in 28 joints before or after vaccination in the overall population. However, COVID-19 vaccination significantly worsened disease activity in patients treated with IL-12/23-i vs  tumor necrosis factor inhibitor (P  =  .019).

Study details: The data come from a prospective observational study including 1765 patients total with PsA (n = 587) or rheumatoid arthritis (n = 1178) treated with targeted therapies who were vaccinated for COVID-19 with any of the available vaccines.

Disclosures: This study was funded by Bristol-Myers Squibb, Galapagos Biopharma Spain SLU, and Roche Farma. Two authors reported ties with various sources, including Galapagos or Roche.

Source: Álvaro-Gracia JM et al. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study. RMD Open. 2023;9(1):e002936 (Mar 16). Doi: 10.1136/rmdopen-2022-002936

Key clinical point: COVID-19 vaccination was not associated with the worsening of disease activity in patients with psoriatic arthritis (PsA) who were treated with targeted therapies; however, COVID-19 vaccination may worsen disease activity in patients treated with interleukin-12/23 inhibitors (IL-12/23-i).

Major finding: The flare rate was not significantly different in the 6 months post-vaccination vs  the pre-vaccination period (P  =  .797), with no significant change in disease activity score in 28 joints before or after vaccination in the overall population. However, COVID-19 vaccination significantly worsened disease activity in patients treated with IL-12/23-i vs  tumor necrosis factor inhibitor (P  =  .019).

Study details: The data come from a prospective observational study including 1765 patients total with PsA (n = 587) or rheumatoid arthritis (n = 1178) treated with targeted therapies who were vaccinated for COVID-19 with any of the available vaccines.

Disclosures: This study was funded by Bristol-Myers Squibb, Galapagos Biopharma Spain SLU, and Roche Farma. Two authors reported ties with various sources, including Galapagos or Roche.

Source: Álvaro-Gracia JM et al. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study. RMD Open. 2023;9(1):e002936 (Mar 16). Doi: 10.1136/rmdopen-2022-002936

Key clinical point: The overall risk for hospital-diagnosed acne is significantly higher in patients with atopic dermatitis (AD), highlighting the need to address comorbid skin diseases simultaneously along with the management of AD.

Major finding: Patients with AD vs control individuals had a 3-fold higher overall risk for hospital-diagnosed acne at ≤18 years (adjusted odds ratio [aOR] 3.44; 95% CI 3.13-3.78) and ≤30 years (aOR 3.15; 95% CI 2.90-3.42) of age.

Study details: The data come from a retrospective registry study that included 70,584 patients with AD aged ≤18 years at the time of their first AD diagnosis and 270,783 matched control individuals without AD.

Disclosures: This study did not receive any funding. Some authors declared serving as investigators and receiving educational grants, consulting fees, or speaker honoraria from various organizations.

Source: Sinikumpu SP et al. The association between atopic dermatitis and acne: A retrospective Finnish nationwide registry study. Br J Dermatol. 2023 (Mar 22). Doi: 10.1093/bjd/ljad086

Key clinical point: The overall risk for hospital-diagnosed acne is significantly higher in patients with atopic dermatitis (AD), highlighting the need to address comorbid skin diseases simultaneously along with the management of AD.

Major finding: Patients with AD vs control individuals had a 3-fold higher overall risk for hospital-diagnosed acne at ≤18 years (adjusted odds ratio [aOR] 3.44; 95% CI 3.13-3.78) and ≤30 years (aOR 3.15; 95% CI 2.90-3.42) of age.

Study details: The data come from a retrospective registry study that included 70,584 patients with AD aged ≤18 years at the time of their first AD diagnosis and 270,783 matched control individuals without AD.

Disclosures: This study did not receive any funding. Some authors declared serving as investigators and receiving educational grants, consulting fees, or speaker honoraria from various organizations.

Source: Sinikumpu SP et al. The association between atopic dermatitis and acne: A retrospective Finnish nationwide registry study. Br J Dermatol. 2023 (Mar 22). Doi: 10.1093/bjd/ljad086

Key clinical point: The overall risk for hospital-diagnosed acne is significantly higher in patients with atopic dermatitis (AD), highlighting the need to address comorbid skin diseases simultaneously along with the management of AD.

Major finding: Patients with AD vs control individuals had a 3-fold higher overall risk for hospital-diagnosed acne at ≤18 years (adjusted odds ratio [aOR] 3.44; 95% CI 3.13-3.78) and ≤30 years (aOR 3.15; 95% CI 2.90-3.42) of age.

Study details: The data come from a retrospective registry study that included 70,584 patients with AD aged ≤18 years at the time of their first AD diagnosis and 270,783 matched control individuals without AD.

Disclosures: This study did not receive any funding. Some authors declared serving as investigators and receiving educational grants, consulting fees, or speaker honoraria from various organizations.

Source: Sinikumpu SP et al. The association between atopic dermatitis and acne: A retrospective Finnish nationwide registry study. Br J Dermatol. 2023 (Mar 22). Doi: 10.1093/bjd/ljad086

Key clinical point: Among malignancies, including breast cancer, melanoma, lymphoma, and non-melanoma skin cancer (NMSC), patients with moderate-to-severe atopic dermatitis (AD) had the highest incidence rate (IR) for NMSC followed by breast cancer and melanoma; NMSC incidence increased with age among patients with moderate but not severe AD.

Major finding: In patients with moderate and severe AD, the IR per 1000 person-years were 4.6 (95% CI 3.9-5.5) and 5.9 (95% CI 3.8-9.2) for NMSC, 2.2 (95% CI 1.6-3.0) and 0.5 (95% CI 0.1-3.9) for breast cancer, and 0.4 (95% CI 0.2-0.7) and 0.6 (95% CI 0.1-2.3) for melanoma, respectively. The NMSC IR increased with increasing age in patients with moderate AD (18-39 vs ≥65 years: 0.1 [95% CI 0.0-0.7] vs 18.0 [95% CI 13.9-23.2]).

Study details: This retrospective study analyzed the data of 7050 adults with moderate-to-severe AD from the Kaiser Permanente Northern California database.

Disclosures: This study was sponsored by Pfizer Inc. Some authors reported ties with various organizations, including Pfizer.

Source: Hedderson MM et al. Rates of malignancies among patients with moderate to severe atopic dermatitis: A retrospective cohort study. BMJ Open. 2023;13(3):e071172 (Mar 10). Doi: 10.1136/bmjopen-2022-071172

Key clinical point: Among malignancies, including breast cancer, melanoma, lymphoma, and non-melanoma skin cancer (NMSC), patients with moderate-to-severe atopic dermatitis (AD) had the highest incidence rate (IR) for NMSC followed by breast cancer and melanoma; NMSC incidence increased with age among patients with moderate but not severe AD.

Major finding: In patients with moderate and severe AD, the IR per 1000 person-years were 4.6 (95% CI 3.9-5.5) and 5.9 (95% CI 3.8-9.2) for NMSC, 2.2 (95% CI 1.6-3.0) and 0.5 (95% CI 0.1-3.9) for breast cancer, and 0.4 (95% CI 0.2-0.7) and 0.6 (95% CI 0.1-2.3) for melanoma, respectively. The NMSC IR increased with increasing age in patients with moderate AD (18-39 vs ≥65 years: 0.1 [95% CI 0.0-0.7] vs 18.0 [95% CI 13.9-23.2]).

Study details: This retrospective study analyzed the data of 7050 adults with moderate-to-severe AD from the Kaiser Permanente Northern California database.

Disclosures: This study was sponsored by Pfizer Inc. Some authors reported ties with various organizations, including Pfizer.

Source: Hedderson MM et al. Rates of malignancies among patients with moderate to severe atopic dermatitis: A retrospective cohort study. BMJ Open. 2023;13(3):e071172 (Mar 10). Doi: 10.1136/bmjopen-2022-071172

Key clinical point: Among malignancies, including breast cancer, melanoma, lymphoma, and non-melanoma skin cancer (NMSC), patients with moderate-to-severe atopic dermatitis (AD) had the highest incidence rate (IR) for NMSC followed by breast cancer and melanoma; NMSC incidence increased with age among patients with moderate but not severe AD.

Major finding: In patients with moderate and severe AD, the IR per 1000 person-years were 4.6 (95% CI 3.9-5.5) and 5.9 (95% CI 3.8-9.2) for NMSC, 2.2 (95% CI 1.6-3.0) and 0.5 (95% CI 0.1-3.9) for breast cancer, and 0.4 (95% CI 0.2-0.7) and 0.6 (95% CI 0.1-2.3) for melanoma, respectively. The NMSC IR increased with increasing age in patients with moderate AD (18-39 vs ≥65 years: 0.1 [95% CI 0.0-0.7] vs 18.0 [95% CI 13.9-23.2]).

Study details: This retrospective study analyzed the data of 7050 adults with moderate-to-severe AD from the Kaiser Permanente Northern California database.

Disclosures: This study was sponsored by Pfizer Inc. Some authors reported ties with various organizations, including Pfizer.

Source: Hedderson MM et al. Rates of malignancies among patients with moderate to severe atopic dermatitis: A retrospective cohort study. BMJ Open. 2023;13(3):e071172 (Mar 10). Doi: 10.1136/bmjopen-2022-071172

Key clinical point: Compared with conventional treatment, enhanced treatment with topical corticosteroids (TCS) significantly reduced the incidence of hen’s egg allergy among infants with atopic dermatitis (AD) but retarded their growth.

Major finding: Infants receiving enhanced vs conventional treatment had a significantly lower incidence of hen’s egg allergy (31.4% vs 41.9%; P = .0028), but demonstrated lower body weight (mean difference −422 g; 95% CI −553 to −292 g) and height (mean difference −0.8 cm; 95% CI −1.22 to −0.33 cm) at 28 weeks of age.

Study details: This randomized controlled trial included 640 infants aged 7-13 weeks with AD who were randomly assigned to receive enhanced therapy (alclometasone dipropionate for the whole face and betamethasone valerate for whole body except face and scalp) followed by maintenance therapy (n = 318) or conventional therapy (alclometasone dipropionate and betamethasone valerate for the affected skin; n = 322).

Disclosures: This study was supported by the Japan Agency for Medical Research and Development (AMED). Some authors reported ties with various organizations, including AMED.

Source: Yamamoto-Hanada K et al on behalf of PACI Study Collaborators. Enhanced early skin treatment for atopic dermatitis in infants reduces food allergy. J Allergy Clin Immunol. 2023 (Mar 22). Doi: 10.1016/j.jaci.2023.03.008

Key clinical point: Compared with conventional treatment, enhanced treatment with topical corticosteroids (TCS) significantly reduced the incidence of hen’s egg allergy among infants with atopic dermatitis (AD) but retarded their growth.

Major finding: Infants receiving enhanced vs conventional treatment had a significantly lower incidence of hen’s egg allergy (31.4% vs 41.9%; P = .0028), but demonstrated lower body weight (mean difference −422 g; 95% CI −553 to −292 g) and height (mean difference −0.8 cm; 95% CI −1.22 to −0.33 cm) at 28 weeks of age.

Study details: This randomized controlled trial included 640 infants aged 7-13 weeks with AD who were randomly assigned to receive enhanced therapy (alclometasone dipropionate for the whole face and betamethasone valerate for whole body except face and scalp) followed by maintenance therapy (n = 318) or conventional therapy (alclometasone dipropionate and betamethasone valerate for the affected skin; n = 322).

Disclosures: This study was supported by the Japan Agency for Medical Research and Development (AMED). Some authors reported ties with various organizations, including AMED.

Source: Yamamoto-Hanada K et al on behalf of PACI Study Collaborators. Enhanced early skin treatment for atopic dermatitis in infants reduces food allergy. J Allergy Clin Immunol. 2023 (Mar 22). Doi: 10.1016/j.jaci.2023.03.008

Key clinical point: Compared with conventional treatment, enhanced treatment with topical corticosteroids (TCS) significantly reduced the incidence of hen’s egg allergy among infants with atopic dermatitis (AD) but retarded their growth.

Major finding: Infants receiving enhanced vs conventional treatment had a significantly lower incidence of hen’s egg allergy (31.4% vs 41.9%; P = .0028), but demonstrated lower body weight (mean difference −422 g; 95% CI −553 to −292 g) and height (mean difference −0.8 cm; 95% CI −1.22 to −0.33 cm) at 28 weeks of age.

Study details: This randomized controlled trial included 640 infants aged 7-13 weeks with AD who were randomly assigned to receive enhanced therapy (alclometasone dipropionate for the whole face and betamethasone valerate for whole body except face and scalp) followed by maintenance therapy (n = 318) or conventional therapy (alclometasone dipropionate and betamethasone valerate for the affected skin; n = 322).

Disclosures: This study was supported by the Japan Agency for Medical Research and Development (AMED). Some authors reported ties with various organizations, including AMED.

Source: Yamamoto-Hanada K et al on behalf of PACI Study Collaborators. Enhanced early skin treatment for atopic dermatitis in infants reduces food allergy. J Allergy Clin Immunol. 2023 (Mar 22). Doi: 10.1016/j.jaci.2023.03.008